Tivic Health exercises option for Neutropenia license; accelerates $500K milestone

Valion Bio, Inc.

Exercised Exclusive Option on March 28, 2025 to license Neutropenia indication of Entolimod from Statera.
Accelerated first milestone payment of $500,000 for IND and Phase 2 study for Neutropenia.
Issued 55,704 common shares and 131.1267 Series A Preferred shares to Statera and Avenue as consideration.
Obligated to develop Neutropenia indication at own cost and pay future milestones up to $2.75M for this indication.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.